Christopher R. Cline Travere Therapeutics, Inc. (TVTX) insider trading activity

Christopher R. Cline is CHIEF FINANCIAL OFFICER of Travere Therapeutics, Inc.. Currently has a direct ownership of 92,083 shares of TVTX, which is worth approximately $2.23 Million. The most recent transaction as insider was on Sep 04, 2025, when has been sold 119 shares (Common Stock) at a price of $19.71 per share, resulting in proceeds of $2,345. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 92.1K

1.12% 3M change

23.44% 12M change

Total Value Held $2.23 Million

Christopher R. Cline Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Sep 04 2025	SELL Open market or private sale	$2,345 $19.71 p/Share	119 Reduced 0.13%	92,083 Common Stock
Sep 03 2025	SELL Open market or private sale	$8,262 $18.2 p/Share	454 Reduced 0.49%	92,202 Common Stock
Aug 27 2025	SELL Open market or private sale	$8,135 $17.31 p/Share	470 Reduced 0.5%	92,656 Common Stock
May 05 2025	SELL Open market or private sale	$37,553 $21.05 p/Share	1,784 Reduced 1.88%	93,126 Common Stock
May 02 2025	BUY Exercise of conversion of derivative security	-	4,920 Added 4.93%	94,910 Common Stock
Apr 11 2025	SELL Open market or private sale	$630 $13.14 p/Share	48 Reduced 0.05%	89,990 Common Stock
Feb 03 2025	SELL Open market or private sale	$104,463 $20.12 p/Share	5,192 Reduced 5.45%	90,038 Common Stock
Jan 31 2025	BUY Grant, award, or other acquisition	-	21,500 Added 18.42%	95,230 Common Stock
Jan 22 2025	SELL Open market or private sale	$16,383 $18.94 p/Share	865 Reduced 1.16%	73,730 Common Stock
Sep 09 2024	SELL Open market or private sale	$28,684 $11.52 p/Share	2,490 Reduced 3.23%	74,595 Common Stock
Sep 05 2024	BUY Grant, award, or other acquisition	-	6,750 Added 8.05%	77,085 Common Stock
Sep 04 2024	SELL Open market or private sale	$4,888 $9.51 p/Share	514 Reduced 0.73%	70,335 Common Stock
Apr 11 2024	SELL Open market or private sale	$363 $6.74 p/Share	54 Reduced 0.08%	70,849 Common Stock
Feb 01 2024	SELL Open market or private sale	$32,567 $8.53 p/Share	3,818 Reduced 5.11%	70,903 Common Stock
Jan 31 2024	BUY Grant, award, or other acquisition	-	25,000 Added 25.07%	74,721 Common Stock
Jan 23 2024	SELL Open market or private sale	$7,736 $9.07 p/Share	853 Reduced 1.69%	49,721 Common Stock
Sep 05 2023	SELL Open market or private sale	$6,722 $14.71 p/Share	457 Reduced 0.9%	50,574 Common Stock
May 10 2023	SELL Open market or private sale	$7,548 $16.59 p/Share	455 Reduced 0.88%	51,031 Common Stock
Apr 11 2023	SELL Open market or private sale	$1,010 $21.49 p/Share	47 Reduced 0.09%	51,486 Common Stock
Feb 01 2023	SELL Open market or private sale	$34,539 $21.75 p/Share	1,588 Reduced 2.99%	51,533 Common Stock
Jan 31 2023	BUY Grant, award, or other acquisition	-	20,250 Added 27.6%	53,121 Common Stock
Jan 24 2023	SELL Open market or private sale	$18,658 $21.9 p/Share	852 Reduced 2.53%	32,871 Common Stock
Sep 01 2022	BUY Grant, award, or other acquisition	-	5,000 Added 12.91%	33,723 Common Stock

CRC

Christopher R. Cline

CHIEF FINANCIAL OFFICER

San Diego, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells TVTX shares.

Notify only if

Value

Insider Trading

Get notified when an Travere Therapeutics, Inc. insider buys or sells TVTX shares.

Notify only if

Operation

Value

Type

News

Receive news related to Travere Therapeutics, Inc.

Track Activities on TVTX

Account